96 black & white illustrations, 17 colour illustrations
Table Of Contents
Dedication Purpose Table of Contents Introduction What is Nanomedicine? What is Translational Medicine? What is Innovation? What is Intellectual Property? From IP to IPO What is Impact? From Atoms to Proteins Atoms and Molecules Atoms of Life Molecules of Life Proteins Genetics and DNA Sequencing DNA and the Genetic Code From DNA to Proteins and Cells History of Genetics Molecular Basis of Genetics DNA Sequencing and the Human Genome Project Sequencing Technologies Chemical Sequencing Sanger Sequencing, NGS and the $1,000 Genome Challenge Second Generation DNA Sequencing Third Generation DNA Sequencing Fourth Generation DNA Sequencing Sequencing Data Analysis Bioethics Business Aspects of Sequencing Technology and the Human Genome Project Post Human Genome Project: Omics Bio-Pharmaceutical R&D Stages of Bio-Pharmaceutical Drug Discovery and Clinical Development Stage 1: Drug Discovery Stage 2: Pre-Clinical Research Stages 3-4: Clinical Trials and FDA Review The Emerging Importance of Biologics Biomarkers and Stratified/Personalized Medicine The Past and Future of Bio-Pharmaceutical R&D Semiconductors: Progress through Collaboration Life Sciences Industry: Exclusive IP Deals and Limited Collaboration IMI and AMP Nanomedicine Computers in Nanomedicine Biocompatible Nanoparticles and Targeted Drug Delivery Dendrimers Liposomes Targeted Drug Delivery The Business of Nanotherapeutics Biomedical and Molecular Imaging Nanodiagnostics Regenerative Medicine: Stem Cells, Gene Therapy, Immunotherapy Impact of Nanomedicine The Gut Microbiome Central Nervous System: Brain and Spinal Cord Cancer and Immunology Cardiovascular Disease Diabetes Infectious Disease Tissue and Organ Transplantation The Healthcare Ecosystem AND BIOMEDICAL RESEARCH FUNDING It's all about the Patient/Consumer The Future of Funding for Basic Biomedical and Translational Research Public Health and Global Health Economics Global View of Healthcare Costs, Infant Mortality and Life Expectancy US Health Statistics Conclusions Acknowledgments References
Dr. Michael Hehenberger is founder of HM NanoMed LLC, Connecticut, USA. He retired after a long career with IBM at the end of 2013. He earned a Dipl. Ing. in physics from the Technical University of Vienna, Austria, and obtained his Ph.D. and Dr. Sc. degrees in quantum chemistry from Uppsala University, Sweden, in 1975-79. He also spent two years at the University of Florida, Gainesville, USA, as visiting associate professor. In 1985, he joined IBM in Stockholm, Sweden, to initiate academic partnerships in computational biology, structural engineering, computer networks, and supercomputing. Throughout his IBM career that took him to European Headquarters in Paris, California (Almaden Research, San Jose), and New York, he has led collaborations with academic and global industrial life sciences organizations. The partnerships were based on the joint desire to extend the frontiers of computational chemistry and biology, information-based medicine, biopharmaceutical research, and nanomedicine. His efforts have been documented in over 40 publications and book chapters.